Vor Biopharma Statistics
Total Valuation
Vor Biopharma has a market cap or net worth of $163.14 million. The enterprise value is $128.84 million.
Important Dates
The next estimated earnings date is Wednesday, March 19, 2025, after market close.
| Earnings Date | Mar 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vor Biopharma has 124.54 million shares outstanding. The number of shares has increased by 10.66% in one year.
| Current Share Class | 124.54M |
| Shares Outstanding | 124.54M |
| Shares Change (YoY) | +10.66% |
| Shares Change (QoQ) | +0.24% |
| Owned by Insiders (%) | 31.97% |
| Owned by Institutions (%) | 15.24% |
| Float | 38.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.23 |
| P/TBV Ratio | 2.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.69, with a Debt / Equity ratio of 0.45.
| Current Ratio | 4.69 |
| Quick Ratio | 4.38 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -90.79% and return on invested capital (ROIC) is -46.50%.
| Return on Equity (ROE) | -90.79% |
| Return on Assets (ROA) | -43.51% |
| Return on Capital (ROIC) | -46.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$669,423 |
| Employee Count | 168 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -46.88% in the last 52 weeks. The beta is -0.51, so Vor Biopharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.51 |
| 52-Week Price Change | -46.88% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.11 |
| Relative Strength Index (RSI) | 52.24 |
| Average Volume (20 Days) | 1,167,159 |
Short Selling Information
The latest short interest is 1.23 million, so 0.99% of the outstanding shares have been sold short.
| Short Interest | 1.23M |
| Short Previous Month | 1.30M |
| Short % of Shares Out | 0.99% |
| Short % of Float | 3.19% |
| Short Ratio (days to cover) | 2.99 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -118.00M |
| Pretax Income | -118.09M |
| Net Income | -112.46M |
| EBITDA | -114.44M |
| EBIT | -118.00M |
| Earnings Per Share (EPS) | -$1.65 |
Full Income StatementBalance Sheet
The company has $62.81 million in cash and $32.85 million in debt, giving a net cash position of $29.96 million or $0.24 per share.
| Cash & Cash Equivalents | 62.81M |
| Total Debt | 32.85M |
| Net Cash | 29.96M |
| Net Cash Per Share | $0.24 |
| Equity (Book Value) | 72.96M |
| Book Value Per Share | 1.06 |
| Working Capital | 52.95M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$99.62 million and capital expenditures -$268,000, giving a free cash flow of -$99.89 million.
| Operating Cash Flow | -99.62M |
| Capital Expenditures | -268,000 |
| Free Cash Flow | -99.89M |
| FCF Per Share | -$0.80 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |